Journal article icon

Journal article

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis

Abstract:

Objective: Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2 that is efficacious in patients with rheumatoid arthritis (RA). This study analyzed changes in lymphocyte cell subsets during baricitinib treatment and correlated such changes with clinical outcomes of ba...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's Version

Actions


Access Document


Files:
Publisher copy:
10.1002/art.40680

Authors


McInnes, IB More by this author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences
Department:
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
ORCID:
0000-0001-7766-6167
Expand authors...
Eli Lilly and Company More from this funder
Incyte Corporation More from this funder
Publisher:
John Wiley and Sons, Ltd. Publisher's website
Journal:
Arthritis and Rheumatology Journal website
Volume:
70
Issue:
12
Pages:
1923-1932
Publication date:
2018-07-29
Acceptance date:
2018-06-27
DOI:
EISSN:
2326-5205
ISSN:
2326-5191
Pubs id:
pubs:860150
URN:
uri:ce0aca2b-d59a-4549-8a52-7f0315b79753
UUID:
uuid:ce0aca2b-d59a-4549-8a52-7f0315b79753
Local pid:
pubs:860150

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP